Professor Steve Schey has contributed throughout the International Haematology community worldwide both in the laboratory and in the translational and clinical research arena. He has trained experts who have become leaders both within the UK and internationally. He has fostered collaborations between the Pharma industry and facilitated the establishment of innovative clinical trials within his field whilst being a passionate advocate for patients.
His skills and energy have led to him serving as President of the British Society for Haematology and chair of the UK Myeloma Forum, and Chair of the National Cancer Research Institute Myeloma Steering Group and National Cancer Research Institute Industry Adoption Panel.
He has published more than 150 original articles and chapters, and has edited a textbook on multiple myeloma. Over the last two decades, he has focused his translational research studies on B cell malignancies, especially multiple myeloma and Castleman’s Disease. Highlights of his contributions to science and medicine include: pioneering novel methods to improve safety and efficacy of autografting and allografting in myeloma; using novel therapies targeting the tumour cell and bone marrow microenvironment to overcome drug resistance and thereby improve patient outcome in myeloma. His team led both preclinical and clinical trials of the immunomodulatory drug lenalidomide, culminating in the rapid NICE approval of these agents for treatment of myeloma.
He also serves as chair of the Lymphoma Research Trust and is a member of the Scientific Advisory Board of the Castleman’s Disease Collaborative Network (CDCN) and Cancer Research UK and UCL Tumour Steering Committee. Currently he is a Professor of Plasma Cell Dyscrasias at Kings’ College, London University and is a Consultant Haematologist leading a dedicated team of specialist healthcare and administrative colleagues to provide a knowledgable, compassionate and innovative service to patients with Castleman Disease at Kings’ College Hospital, London.